丹麦、芬兰和瑞典吸入哮喘药物和口服皮质类固醇使用强度的地区差异

IF 1.8 Q3 RESPIRATORY SYSTEM European Clinical Respiratory Journal Pub Date : 2022-05-02 DOI:10.1080/20018525.2022.2066815
L. Lehtimäki, M. Arvidsson, B. Erdemli, C. Nan, T. Nguyen, Aditya Samant, G. Telg
{"title":"丹麦、芬兰和瑞典吸入哮喘药物和口服皮质类固醇使用强度的地区差异","authors":"L. Lehtimäki, M. Arvidsson, B. Erdemli, C. Nan, T. Nguyen, Aditya Samant, G. Telg","doi":"10.1080/20018525.2022.2066815","DOIUrl":null,"url":null,"abstract":"ABSTRACT Oral corticosteroids (OCS) are often prescribed to patients with asthma that remains uncontrolled with maintenance therapy. We performed a real-world analysis to describe the geographic distributions of patients with asthma and OCS dispensed in Nordic countries. This observational, retrospective study examined patient-level data from nationally prescribed drug registries from January to December 2018 for individuals aged ≥12 years in Denmark, Finland, and Sweden. Using an algorithm based on asthma treatment combinations defined by the Global Initiative for Asthma (GINA), we identified patients with asthma, those on GINA Step 4–5 treatments, and those being dispensed ≥2 courses of OCS and determined volumes of OCS dispensed to these patients over the 1-year analysis period. Data were plotted geographically within each country using colour-coded heat maps. The overall asthma prevalence rates were 7.4% in Denmark, 11.6% in Finland, and 8.1% in Sweden. In Denmark, Finland, and Sweden, respectively, the frequencies of patients on GINA Step 4–5 treatments were 19%, 15%, and 16%; among whom 10%, 23%, and 5% received ≥2 courses of OCS. The rates of patients on GINA Step 4–5 treatments who were dispensed OCS in each country were 23%, 30%, and 46%, of which 22%, 17%, and 10% were dispensed doses averaging ≥5 mg/day over the year. Heat maps revealed considerable heterogeneity in geographic densities of patients with asthma and OCS claims within each country. Taken together, these results demonstrate regional variations in estimated asthma severity, control, and OCS dispensed within and between countries. Patterns of medication use suggest that a high proportion of patients in Denmark, Finland, and Sweden are on GINA Step 4–5 treatments, many of whom are dispensed OCS; this poses a considerable corticosteroid burden to these patients. Geographic differences in medication use within and between Nordic countries may reflect variations in population characteristics and/or treatment approaches.","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2022-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Regional variation in intensity of inhaled asthma medication and oral corticosteroid use in Denmark, Finland, and Sweden\",\"authors\":\"L. Lehtimäki, M. Arvidsson, B. Erdemli, C. Nan, T. Nguyen, Aditya Samant, G. Telg\",\"doi\":\"10.1080/20018525.2022.2066815\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"ABSTRACT Oral corticosteroids (OCS) are often prescribed to patients with asthma that remains uncontrolled with maintenance therapy. We performed a real-world analysis to describe the geographic distributions of patients with asthma and OCS dispensed in Nordic countries. This observational, retrospective study examined patient-level data from nationally prescribed drug registries from January to December 2018 for individuals aged ≥12 years in Denmark, Finland, and Sweden. Using an algorithm based on asthma treatment combinations defined by the Global Initiative for Asthma (GINA), we identified patients with asthma, those on GINA Step 4–5 treatments, and those being dispensed ≥2 courses of OCS and determined volumes of OCS dispensed to these patients over the 1-year analysis period. Data were plotted geographically within each country using colour-coded heat maps. The overall asthma prevalence rates were 7.4% in Denmark, 11.6% in Finland, and 8.1% in Sweden. In Denmark, Finland, and Sweden, respectively, the frequencies of patients on GINA Step 4–5 treatments were 19%, 15%, and 16%; among whom 10%, 23%, and 5% received ≥2 courses of OCS. The rates of patients on GINA Step 4–5 treatments who were dispensed OCS in each country were 23%, 30%, and 46%, of which 22%, 17%, and 10% were dispensed doses averaging ≥5 mg/day over the year. Heat maps revealed considerable heterogeneity in geographic densities of patients with asthma and OCS claims within each country. Taken together, these results demonstrate regional variations in estimated asthma severity, control, and OCS dispensed within and between countries. Patterns of medication use suggest that a high proportion of patients in Denmark, Finland, and Sweden are on GINA Step 4–5 treatments, many of whom are dispensed OCS; this poses a considerable corticosteroid burden to these patients. Geographic differences in medication use within and between Nordic countries may reflect variations in population characteristics and/or treatment approaches.\",\"PeriodicalId\":11872,\"journal\":{\"name\":\"European Clinical Respiratory Journal\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2022-05-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Clinical Respiratory Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/20018525.2022.2066815\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Clinical Respiratory Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20018525.2022.2066815","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 1

摘要

口服皮质类固醇(OCS)常用于维持治疗仍不受控制的哮喘患者。我们进行了现实世界的分析,以描述北欧国家哮喘和OCS患者的地理分布。这项观察性回顾性研究检查了2018年1月至12月丹麦、芬兰和瑞典国家处方药登记处的患者水平数据,涉及年龄≥12岁的个体。使用基于全球哮喘倡议(GINA)定义的哮喘治疗组合的算法,我们确定了哮喘患者,接受GINA步骤4-5治疗的患者,以及分配≥2个疗程OCS的患者,并确定了在1年的分析期内分配给这些患者的OCS量。使用彩色编码的热图绘制了每个国家的地理数据。总体哮喘患病率丹麦为7.4%,芬兰为11.6%,瑞典为8.1%。在丹麦、芬兰和瑞典,接受GINA步骤4-5治疗的患者频率分别为19%、15%和16%;其中10%、23%和5%接受了≥2个疗程的OCS治疗。在每个国家接受GINA第4-5步治疗的患者中,分配OCS的比例分别为23%、30%和46%,其中22%、17%和10%的患者在一年中分配的平均剂量≥5mg /天。热图显示,每个国家哮喘患者的地理密度和OCS索赔存在相当大的异质性。综上所述,这些结果表明在估计的哮喘严重程度、控制和国家内部和国家之间分配的OCS方面存在区域差异。药物使用模式表明,在丹麦、芬兰和瑞典,接受GINA第4-5步治疗的患者比例很高,其中许多人使用OCS;这给这些患者带来了相当大的皮质类固醇负担。北欧国家内部和国家之间药物使用的地理差异可能反映了人口特征和/或治疗方法的差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Regional variation in intensity of inhaled asthma medication and oral corticosteroid use in Denmark, Finland, and Sweden
ABSTRACT Oral corticosteroids (OCS) are often prescribed to patients with asthma that remains uncontrolled with maintenance therapy. We performed a real-world analysis to describe the geographic distributions of patients with asthma and OCS dispensed in Nordic countries. This observational, retrospective study examined patient-level data from nationally prescribed drug registries from January to December 2018 for individuals aged ≥12 years in Denmark, Finland, and Sweden. Using an algorithm based on asthma treatment combinations defined by the Global Initiative for Asthma (GINA), we identified patients with asthma, those on GINA Step 4–5 treatments, and those being dispensed ≥2 courses of OCS and determined volumes of OCS dispensed to these patients over the 1-year analysis period. Data were plotted geographically within each country using colour-coded heat maps. The overall asthma prevalence rates were 7.4% in Denmark, 11.6% in Finland, and 8.1% in Sweden. In Denmark, Finland, and Sweden, respectively, the frequencies of patients on GINA Step 4–5 treatments were 19%, 15%, and 16%; among whom 10%, 23%, and 5% received ≥2 courses of OCS. The rates of patients on GINA Step 4–5 treatments who were dispensed OCS in each country were 23%, 30%, and 46%, of which 22%, 17%, and 10% were dispensed doses averaging ≥5 mg/day over the year. Heat maps revealed considerable heterogeneity in geographic densities of patients with asthma and OCS claims within each country. Taken together, these results demonstrate regional variations in estimated asthma severity, control, and OCS dispensed within and between countries. Patterns of medication use suggest that a high proportion of patients in Denmark, Finland, and Sweden are on GINA Step 4–5 treatments, many of whom are dispensed OCS; this poses a considerable corticosteroid burden to these patients. Geographic differences in medication use within and between Nordic countries may reflect variations in population characteristics and/or treatment approaches.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.80
自引率
0.00%
发文量
15
审稿时长
16 weeks
期刊最新文献
Translation and cross-cultural adaptation of the self evaluation of breathing questionnaire (SEBQ) into Danish. Factors behind favorable long-term lung cancer survival in Norway compared to Denmark: a retrospective cohort study. Socioeconomic status and emergency department visits in adults with a history of severe childhood asthma: a register-based study. Comorbid allergy and rhinitis and patient-related outcomes in asthma and COPD: a cross-sectional study. Lung function measurements in the Greenlandic Inuit population: results from the Greenlandic health survey 2017-2019.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1